Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
Diabetes, Obesity and Metabolism · 2025-08 · 27 (S7) · 42-54
DOI: 10.1111/dom.16645 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.07.2025. Verfasst von Luděk Horváth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Insulin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union, European Commission.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Until recently, people with type 2 diabetes mellitus (PwT2DM) with poor glycaemic control on oral antidiabetic medication were initiated on insulin therapy. While insulin‐based therapies have been efficient in reducing hyperglycaemia, they have also been linked with an increased risk of hypoglycaemia, increased treatment burden, and weight gain. The advent of novel classes of antidiabetic agents, such as glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) or sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) presents a significant shift in the T2DM treatment algorithms. These medications are not only efficient in the reduction of glycaemia but are also able to reduce weight and have cardiovascular and renal benefits. PwT2DM on complex insulin regimens can now benefit from therapy simplification, taking advantage of once‐daily fixed‐ratio combinations (FRC) of basal insulin and glucagon‐like peptide‐1 receptor agonist. Current evidence suggests that this approach is equally efficient in terms of glycaemic control with the additional benefit of the reduction of body weight, total daily dose of insulin, and the number of insulin injections administered per day with no increase or reduction of hypoglycaemia. The primary aim of this review is to present the current evidence supporting the simplification of complex insulin regimens in PwT2DM with the two currently available FRCs on the market (insulin glargine 100 U/mL and GLP‐1 RA lixisenatide [iGlarLixi] or insulin degludec and GLP‐1 RA liraglutide [IDegLira]) and to provide a simple clinical practice‐oriented algorithm for clinicians based on the currently available evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
- General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID-Profile: Luděk Horváth, Peter Novodvorský, Martin Haluzík
Förderung
- European Union
- European Commission
Zitieren
APA
Horváth, L., Novodvorský, P., & Haluzík, M. (2025). Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist. Diabetes, Obesity and Metabolism, 27(S7), 42-54. https://doi.org/10.1111/dom.16645
Vancouver
Horváth L, Novodvorský P, Haluzík M. Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist. Diabetes, Obesity and Metabolism. 2025;27(S7):42-54. doi:10.1111/dom.16645
BibTeX
@article{Horvth2025,
author = {Horváth, Luděk and Novodvorský, Peter and Haluzík, Martin},
title = {Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {S7},
pages = {42--54},
doi = {10.1111/dom.16645}
}
EUVIMED